Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
However, because this combo is not as effective as the current standard treatment, the search for new options continues.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
This finding refers specifically to viral mutations conferring resistance to the emtricitabine component of the two-drug tablet Truvada.
The bacterial infection, passed through contact with feces, can prompt diarrhea, stomach cramps, fever, vomiting, weakness and fatigue.
Fostemsavir offers HIV treatment hope to those with no other options.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
HIV, anti-vaxxers, dengue fever and weak primary health care make the World Health Organization’s list of priorities.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.